Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator (“XOMA Royalty”), announce they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty (“Sub”), has agreed to acquire the entire issued and to be issued share capital of Mural for cash. Under the terms of the Acquisition and subject to certain conditions, at closing, each Mural Shareholder (i) would receive a base cash price of $2.035 per share (the “Base Price Per Share”) and (ii) may receive an additional cash amount per share of up to $0.205 (the “Additional Price Per Share”).
Read the full article: Mural Oncology Announces Entry into Agreement to Be Acquired by XRA 5 Corp., a Wholly Owned Subsidiary of Xoma Royalty //
Source: https://www.globenewswire.com/news-release/2025/08/20/3136413/7281/en/Mural-Oncology-Announces-Entry-into-Agreement-to-be-Acquired-by-XRA-5-Corp-a-wholly-owned-subsidiary-of-XOMA-Royalty-for-between-2-035-and-2-24-in-Cash-per-Share.html